BlueCross BlueShield of Tennessee Medical Policy Manual

Eculizumab (Soliris®)

Requires Step Therapy See “Step Therapy Requirements for Provider Administered Specialty Medications” Document at: https://www.bcbst.com/docs/providers/Comm_BC_PAD_Step_Therapy_Guide.pdf

IMPORTANT REMINDER

We develop Medical Policies to provide guidance to Members and Providers.  This Medical Policy relates only to the services or supplies described in it.  The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy.  For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed.  If there is a conflict between the Medical Policy and a health plan or government program (e.g., TennCare), the express terms of the health plan or government program will govern.

POLICY

I.        INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered covered benefits provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications

A.    Paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis

B.    Atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy

C.  Generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) antibody positive

D.  Neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive

Limitations of Use: Soliris is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).

All other indications are considered experimental/investigational and not medically necessary.

II.        DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review for new requests for treatment of:

A .For initial requests:

1. Atypical hemolytic uremic syndrome: ADAMTS 13 level

2. Paroxysmal nocturnal hemoglobinuria: flow cytometry used to show results of glycosylphosphatidylinositol-      anchored proteins (GPI-APs) deficiency

3. Generalized myasthenia gravis: anti-acetylcholine receptor (AchR) antibody positive, clinical classification of myasthenia gravis score, MG activities of daily living score, use of IVIG, use of two immunosuppressive therapies

4. Neuromyelitis optica spectrum disorder: immunoassay used to confirm anti-aquaporin-4 (AQP4) antibody is present

III.        For continuation requests: Chart notes or medical record documentation supporting positive clinical response

   IV.        CRITERIA FOR INITIAL APPROVAL

A.    Atypical hemolytic uremic syndrome

  Authorization of 6 months may be granted for treatment of atypical hemolytic uremic syndrome not caused by Shiga toxin when all of the following criteria are met:

1.     ADAMTS 13 activity level above 5%

2.     Absence of Shiga toxin

B.    Paroxysmal nocturnal hemoglobinuria

 Authorization of 6 months may be granted for treatment of paroxysmal nocturnal hemoglobinuria (PNH) when all of the following criteria are met:

  1.     The diagnosis of PNH was confirmed by detecting a deficiency of glycosylphosphatidylinositol-anchored proteins (GPI-APs) as demonstrated by either of the following:

a.     At least 5% PNH cells

b.     At least 51% of GPI-AP deficient poly-morphonuclear cells

2.     Flow cytometry is used to demonstrate GPI-APs deficiency

C.    Generalized myasthenia gravis (gMG) Authorization of 6 months may be granted for treatment of generalized myasthenia gravis (gMG) when all of the following criteria are met:

1.  Anti-acetylcholine receptor (AchR) antibody positive

2.  Myasthenia Gravis Foundation of America (MGFA) clinical classification II to IV

3.  MG activities of daily living (MG-ADL) total score ≥6

4.  Meets both of the following:

a.     Member has had an inadequate response to at least two immunosuppressive therapies listed below:

                                  i.    azathioprine

                                 ii.    cyclosporine

                                iii.    mycophenolate mofetil

                                iv.    tacrolimus

                                 v.    methotrexate

                                vi.    cyclophosphamide

                               vii.    rituximab

b.     Member has inadequate response to chronic IVIG

D.      Neuromyelitis Optica Spectrum Disorder (NMOSD)

   Authorization of 6 months may be granted for treatment of neuromyelitis optica spectrum disorder (NMOSD) when all of the following criteria are met:

 1.     Anti-aquaporin-4 (AQP4) antibody positive

 2.     Member exhibits one of the following core clinical characteristics of NMOSD:

a.     Optic neuritis

b.     Acute myelitis

c.     Area postrema syndrome (episode of otherwise unexplained hiccups or nausea and vomiting)

d.     Acute brainstem syndrome

e.     Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions

f.      Symptomatic cerebral syndrome with NMOSD-typical brain lesions

     3.     The member will not receive the requested drug concomitantly with other biologics for the treatment of NMOSD.

            V.        CONTINUATION OF THERAPY

A. Atypical hemolytic uremic syndrome

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization when there is no evidence of unacceptable toxicity or disease progression while on the current regimen and demonstrate a positive response to therapy (e.g., normalization of lactate dehydrogenase (LDH) levels, platelet counts).

B. Paroxysmal nocturnal hemoglobinuria

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization when there is no evidence of unacceptable toxicity or disease progression while on the current regimen and demonstrate a positive response to therapy (e.g., improvement in hemoglobin levels, normalization of lactate dehydrogenase [LDH] levels).

C. Generalized myasthenia gravis (gMG)

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization when there is no evidence of unacceptable toxicity or disease progression while on the current regimen and demonstrate a positive response to therapy (e.g., improvement in MG-ADL score, changes compared to baseline in Quantitative Myasthenia Gravis (QMG) total score).

D. Neuromyelitis optica spectrum disorder (NMOSD)

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization when all of the following criteria are met:

1.     There is no evidence of unacceptable toxicity or disease progression while on the current regimen.

2.     The member demonstrates a positive response to therapy (e.g., reduction in number of relapses).

3.     The member will not receive the requested drug concomitantly with other biologics for the treatment of NMOSD.

   VI.        DOSAGE AND ADMINISTRATION

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

MEDICATION QUANTITY LIMITS

APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS

BlueCross BlueShield of Tennessee’s Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.

ADDITIONAL INFORMATION  

For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).

REFERENCES

1.     Soliris [package insert]. New Haven, CT: Alexion Pharmaceuticals, Inc.; November 2020.

2.     Loirat C, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. Published online: April 11, 2015. 

3.     Parker CJ. Management of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitory therapy. Hematology. 2011; 21-29.

4.     Sanders D, Wolfe G, Benatar M et al. International consensus guidance for management of myasthenia gravis. Neurology. 2021; 96 (3) 114-122 .

5.     Jaretzki A, Barohn RJ, Ernstoff RM et al.  Myasthenia Gravis: Recommendations for Clinical Research Standards.  Ann Thorac Surg. 2000;70: 327-34.

6.     Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. NEJM. 2006;335:1233-43.

7.     Howard JF, Utsugisawa K, Benatar M.  Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis (REGAIN); a phase 3, randomized, double-blind, placebo-controlled, multicenter study.  Lancet Neurol. 2017 Oct 20.  http://dx.doi.org/10.1016/S1474-4422(17)30369-1Ingenix HCPCS Level II, Expert 2011.

8.     Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111(4):1840-1847.

9.     Borowitz MJ, Craig F, DiGiuseppe JA, et al. Guidelines for the Diagnosis and Monitoring of Paroxysmal Nocturnal Hemoglobinuria and Related Disorders by Flow Cytometry. Cytometry B Clin Cytom. 2010: 78: 211-230.

10.  Preis M, Lowrey CH. Laboratory tests for paroxysmal nocturnal hemoglobinuria (PNH). Am J Hematol. 2014;89(3):339-341.

11.  Lee JW, Sicre de Fontbrune F, Wong LL, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: The 301 study. Blood. 2018 Dec 3; pii: blood-2018-09-876136.

12.  Pittock SJ, Berthele A, Kim HJ, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019 May 3. doi: 10.1056/NEJMoA1900866.

13.  Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85:177-189.

14.  Parker CJ. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. Hematology Am Soc Hematol Educ Program. 2016;2016(1):208-216.

15.  Dezern AE, Borowitz MJ. ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 1 - clinical utility. Cytometry B Clin Cytom. 2018 Jan;94(1):16-22.

ORIGINAL EFFECTIVE DATE: 12/8/2007

MOST RECENT REVIEW DATE: 7/9/2024

ID_CHS

Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.

This document has been classified as public information